Published: Fri, May 19, 2017
Industry | By Dora Warner

Integra Lifesciences Holdings Corp (IART) Earns Media Impact Score of 0.11


May 16, 2017 EdwardsLifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that new 1-year data from a large European post-approval study of the Edwards SAPIEN 3 transcatheter heart valve demonstrated positive patient outcomes including high survival rates and low rates of stroke and paravalvular leak. BLB&B Advisors LLC's holdings in Edwards Lifesciences Corp were worth $203,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Finally, Brown Advisory Securities LLC purchased a new stake in Edwards Lifesciences Corp during the third quarter worth about $203,000. Old Mutual Global Investors UK Ltd. raised its stake in Edwards Lifesciences Corp by 51.8% in the third quarter. Conning Inc. now owns 5,306 shares of the medical research company's stock valued at $640,000 after buying an additional 50 shares during the period. Tracking ROA value which gives an idea as to how efficient management is at using its assets to generate earnings. They now have a "buy" rating on the stock. Finally, Great West Life Assurance Co. Fuller & Thaler Asset Management Inc. increased its position in shares of Edwards Lifesciences Corp by 87.5% in the third quarter. Great West Life Assurance Co. The company had a trading volume of 1,663,254 shares. Insiders own 2.37% of the company's stock.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 0.10% during midday trading on Thursday, reaching $111.95. The stock is trading $99.21 its 50-day moving average by -14.44%. The firm has a market cap of $23.46 billion, a price-to-earnings ratio of 37.18 and a beta of 0.53. Looking at the stock's movement on the chart, Edwards Lifesciences Corporation recorded a 52-week high of $121.75.

Stock of Edwards Lifesciences Corporation (NYSE:EW) now have an ABR of 1.46.which is marked on a basic 1 to 5 scale, where 1 stands for a Strong Buy and 5 represents Strong Sell. The company had revenue of $883.50 million during the quarter, compared to the consensus estimate of $776.51 million. It has a return on equity (ROE) of 25.00%.

Trump denies asking Comey to end Flynn investigation
Trump and his advisers dismiss as "fake news" invented by the major news media to bring down his presidency. "Believe me. Next question", he said, speaking at a press conference with the Colombian president.


The High Revenue estimate is predicted as 855 Million, while the Low Revenue Estimate prediction stands at 822.2 Million. During the same quarter a year ago, the firm earned $0.71 earnings per share. The company's revenue for the quarter was up 26.7% compared to the same quarter previous year. Nomura initiated Edwards Lifesciences Corp (NYSE:EW) rating on Thursday, March 17.

ILLEGAL ACTIVITY WARNING: This story was reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was illegally stolen and reposted in violation of worldwide copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/18/howland-capital-management-llc-increases-position-in-edwards-lifesciences-corp-ew-updated-updated-updated.html.

EW has been the subject of a number of recent research reports. Goldman Sachs Group Inc started coverage on shares of Edwards Lifesciences Corp in a research report on Tuesday.

Shares of Edwards Lifesciences Corp (NYSE:EW) inclined 0.19% to $113.65.

Charlie Hunnam turned down a Game of Thrones cameo
The plot follows a young "Arthur" who runs the back streets of "Londinium" with his crew, unaware of his royal lineage until he draws the sword "Excalibur" from the stone.


4/26/2017 - Edwards Lifesciences Corp was downgraded by analysts at Vetr from a "strong-buy" rating to a "hold" rating. They set a "conviction-buy" rating and a $138.00 price target for the company.

02/02/2017 - Edwards Lifesciences Corporation was downgraded to "market perform" by analysts at Leerink Swann. Edwards Lifesciences Corp now has an average rating of "Buy" and a consensus target price of $119.77. Also, VP Patrick B. Verguet sold 11,500 shares of the company's stock in a transaction that occurred on Monday, May 15th. The stock gained 1.63% in total of its share price. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, the shares of the company have changed 27.00% and performed 24.88% over the last six months.

On 5/4/2017 Donald E. Bobo, Jr., VP, sold 34,120 with an average share price of $109.98 per share and the total transaction amounting to $3,752,517.60.

Two Civilians Killed, Three Injured In Pak Shelling Along LoC
Schools have also been shut along the LoC in Balakote sector in Poonch and people have been asked not to move out in border areas. India and Pakistan have a long history of bitter relations over Kashmir, a Himalayan territory claimed by both.


Like this: